SCHEMBL22925951

SCHEMBL22925951

Cn1nc(-c2ccc(C(F)(F)F)cn2)cc1Nc1ccc(/C(N)=N\O)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
KIF11 P52732 1/20 0.34
BACE1 P56817 6/20 0.34
BACE2 Q9Y5Z0 4/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TGFBR1 P36897 2/20 0.33
NTRK1 P04629 1/20 0.33
CSNK1D P48730 1/20 0.33
CSNK1E P49674 1/20 0.33
KIT P10721 1/20 0.32
FLT3 P36888 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
AURKA O14965 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
PLK1 P53350 1/20 0.32
CCNA1 P78396 1/20 0.32
BTK Q06187 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28733666 1.00 MAPK1 (0.38) MAPK1KMT2AKIF11BACE1BACE2
SCHEMBL22925765 1.00 MAPK1 (0.38) MAPK1KMT2AKIF11BACE1BACE2
SCHEMBL22925706 0.89 MAPT (0.38) MAPK1KMT2AKIF11NPSR1KIT
SCHEMBL22925993 0.89 MAPT (0.38) MAPK1KMT2AKIF11NPSR1KIT
SCHEMBL28733661 0.89 MAPT (0.38) MAPK1KMT2AKIF11NPSR1KIT
SCHEMBL28733752 0.83 MAPK1 (0.37) MAPK1KMT2AKIF11BACE1BACE2
SCHEMBL22925862 0.83 MAPK1 (0.37) MAPK1KMT2AKIF11BACE1BACE2
SCHEMBL22925945 0.79 LRRK2 (0.40) KIF11
SCHEMBL22925818 0.78 MAPK1 (0.39) MAPK1KMT2AKIF11BACE1BACE2
SCHEMBL22925768 0.78 MAPK1 (0.39) MAPK1KMT2AKIF11BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB MAPK1 567/4885KMT2A 3735/4885KIF11 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.